

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-17. (Cancelled)

18. (Previously Presented) A method of preventing or treating graft versus host reaction in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) an antibody or a portion thereof that binds to human AILIM and inhibits proliferation of an AILIM-expressing cell or production of interferon-gamma or interleukin-4 by an AILIM-expressing cell, and (b) a pharmaceutically acceptable carrier.

19-32. (Cancelled)

33. (New) The method of claim 18, wherein the antibody or portion thereof is a monoclonal antibody.

34. (New) The method of claim 33, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

35. (New) The method of claim 18, wherein the antibody or portion thereof is an F(ab')₂ fragment, an Fab' fragment, an Fab fragment, an Fv fragment, or a single domain antibody.